The Multiple System Atrophy Coalition has compiled a list of experimental treatments currently in development for MSA. The graphic below will enable you to see at a glance how far along they are in the drug development process. To assist you in finding more detailed information we’ve divided the list into Clinical Trials and Laboratory Studies. Explore the links below to learn more.
Remember to check back regularly to find out what’s new in the Multiple System Atrophy Treatment Pipeline and be sure to Sign Up Here for our newsletter mailing list to stay informed of the latest updates.
January 9, 2023: Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
September 20, 2022: Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
August 25, 2022: Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
July 26, 2022: Lundbeck conducting largest study ever to observe early-stage multiple system atrophy
April 27, 2022: Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
April 4, 2022: Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)
March 16, 2022: AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
November 8, 2021: Lundbeck launches a phase II study for potential new treatment of multiple system atrophy
October 26, 2021: Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
October 19, 2021: Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
October 15, 2021: The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy
September 29, 2021: Florey Institute of Neuroscience and Mental Health publishes research funded by The Multiple System Atrophy Coalition
September 29, 2021: Lupin Launches Droxidopa Capsules in the United States
September 27, 2021: Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program
September 23, 2021: Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
September 22, 2021: ICBII Announces Approval of Its 7th Patent on Blood-Brain Barrier Permeable Technology, Moving Closer to Clinical Trials on its drugs for Alzheimer’s, Parkinson’s, and Other Neuro-Degenerative Diseases
September 15, 2021: Theravance Biopharma, Inc. announces top-line results from a Phase 3 study of Ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension
July 27, 2021: AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate
July 15, 2021: New Publication Demonstrates ATH434 is Neuroprotective
July 1, 2021: Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer’s and Parkinson’s
June 23, 2021: European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
June 11, 2021: Updated Q&A on Verdiperstat
May 2021: Updates on Biohaven’s study to evaluate the efficacy and safety of BHV- 3241 (Verdiperstat)
April 21, 2021: ATH434 protects brain cells and improves motor function in Parkinsonian disorder
February 5, 2021: Biohaven Shares Verdiperstat’s Mechanism of Action
December 23, 2020: MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson’s Disease
December 3, 2020: Inhibikase Advances Development Program for Multiple System Atrophy (MSA) Based on Demonstration of Key Role of c-Abl Kinase in MSA Neurodegeneration
November 16, 2020: Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases (ATH434)
November 6, 2020: Effect of the Initial Maintenance Dose of Droxidopa on Treatment Persistence in Patients With Neurogenic Orthostatic Hypotension
November 6, 2020: M-STAR, an Ongoing Phase 3 Study in Participants with Multiple System Atrophy–Baseline Characteristics (Verdiperstat)
October 27, 2020: Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study (ATH434)
October 16, 2020: IXICO and NYU Langone Health Sign Agreement to Develop Novel Imaging Markers in Multiple System Atrophy (Sirolimus)
September 24, 2020: Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance
September 3, 2020: A Phase 1 Randomized Trial of Specific Active α‐Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy
August 5, 2020: MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation
August 4, 2020: New data independently confirms and extends laboratory findings and expands safety profile of ATH434 (PBT-434)
July 21, 2020: Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy
July 1, 2020: Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 (PBT-434)
April 30, 2020: MSA Coalition Blog – Caution When it Comes to Stem Cells for MSA
April 16, 2020: MSA Coalition Blog – Q & A about Verdiperstat Clinical Trial
April 14, 2020: Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
March 18, 2020: Biohaven’s Verdiperstat Receives Fast Track Designation for the Treatment of Multiple System Atrophy
January 21, 2020: Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272
January 14, 2020: European Commission approves Orphan Designation for Alterity’s lead drug candidate (PBT-434)
December 18, 2019: MODAG Initiates First-in-Human Phase 1 Clinical Trial for Anle138b
December 18, 2019: Nilotinib Study Results Show People with Parkinson’s Disease Should Pass on This Drug
November 18, 2019: FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models. (Fingolimod)
November 4, 2019: Researchers begin trial of drug to slow progression of neurodegenerative condition Multiple System Atrophy (Exendin-4)
October 5, 2019: A vaccine for Parkinson’s disease shows promising results (PD01A)
August 2, 2019: Green Tea Extract Shows No Significant Benefit for Multiple System Atrophy (ECGC)
CLINICAL TRIALS & STUDIES
EXPERIMENTAL LAB WORK
Not sure what to look for in a clinical trial? Watch this informative video: Helping you understand clinical trials
Are you interested in participating in a clinical trial? Visit www.clinicaltrials.gov, enter the name of the disease and you’ll be able to stay abreast of the latest clinical trial news. You can also enroll in the Fox Trial Finder which not only allows you to share your information for future research studies but will also inform you of any research study or clinical trial for which you qualify.
Join the Global MSA Registry
The Global MSA Patient Registry (GLoMSAR) connects people who have MSA and their care partners to physicians and researchers focused on the disease.
More than 1,000 people with MSA are part of the registry, which also provides them with updates on treatments, news, and clinical trial opportunities. The registry also enables neurologists who specialize in treating MSA to contact eligible patients to participate in clinical trials and speed up the testing of potential new therapies.
More MSA Research Highlights
In this video, recorded at the MSA Coalition’s annual conference in September 2019, Dr. Gregor Wenning, Chairman of the MSA Coalition’s Scientific Advisory Board discusses MSA Coalition funded research and promising treatments to watch.
A Track Record of Success
Explore reports and articles from MSA Coalition supported research.
Building Hope Through Research
Since 2013, the Multiple System Atrophy Coalition has funded 55 MSA focused research projects for a total of $3.5 Million.
Explore the links below to learn more about our research goals and the outcomes of our funded projects.
Click on each category to read about these exciting research projects.
- Pathogenesis: Uncovering the cause of MSA
- Diagnostic Biomarkers: Improving methods for better diagnosis
- Preclinical: Evaluating potential new treatments in the lab
- Clinical: Facilitating clinical studies of potential new treatments in MSA patients
We are making an impact!
- See slides of the latest research results from our funded projects
- Explore the MSA treatment pipeline, including links to current clinical trials
- Check out the growing number of peer reviewed research articles that have arisen from our MSA Coalition funded grants.
© Copyright The Multiple System Atrophy Coalition 1989-2022. All Rights Reserved.